142 related articles for article (PubMed ID: 34449146)
41. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma.
Burkhardt B; Woessmann W; Zimmermann M; Kontny U; Vormoor J; Doerffel W; Mann G; Henze G; Niggli F; Ludwig WD; Janssen D; Riehm H; Schrappe M; Reiter A
J Clin Oncol; 2006 Jan; 24(3):491-9. PubMed ID: 16421426
[TBL] [Abstract][Full Text] [Related]
42. Treatment of pediatric Burkitt lymphoma in Turkey.
Celkan TT; Bariş S; Ozdemir N; Ozkan A; Apak H; Doğru O; Karaman S; Canbolat A; Ozdil M; Aki H; Adaletli I; Kurugoglu S; Hallac M; Yildiz I
J Pediatr Hematol Oncol; 2010 Oct; 32(7):e279-84. PubMed ID: 20736844
[TBL] [Abstract][Full Text] [Related]
43. Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children.
Spreafico F; Massimino M; Luksch R; Casanova M; Cefalo GS; Collini P; Ferrari A; Polastri D; Terenziani M; Gasparini M; Fossati-Bellani F
J Clin Oncol; 2002 Jun; 20(12):2783-8. PubMed ID: 12065554
[TBL] [Abstract][Full Text] [Related]
44. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
Kujawski LA; Longo WL; Williams EC; Turman NJ; Brandt N; Mosher DF; Eickhoff JC; Kahl BS
Cancer Invest; 2007 Mar; 25(2):87-93. PubMed ID: 17453819
[TBL] [Abstract][Full Text] [Related]
45. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
Kojima Y; Hagiwara S; Uehira T; Ajisawa A; Kitanaka A; Tanuma J; Okada S; Nagai H
Jpn J Clin Oncol; 2014 Apr; 44(4):318-23. PubMed ID: 24558129
[TBL] [Abstract][Full Text] [Related]
46. Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center.
Mora J; Filippa DA; Qin J; Wollner N
Cancer; 2003 Sep; 98(6):1283-91. PubMed ID: 12973853
[TBL] [Abstract][Full Text] [Related]
47. Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group.
Seidemann K; Tiemann M; Lauterbach I; Mann G; Simonitsch I; Stankewitz K; Schrappe M; Zimmermann M; Niemeyer C; Parwaresch R; Riehm H; Reiter A;
J Clin Oncol; 2003 May; 21(9):1782-9. PubMed ID: 12721255
[TBL] [Abstract][Full Text] [Related]
48. Therapy of B-cell acute lymphoblastic leukaemia in childhood: the BFM experience.
Reiter A
Baillieres Clin Haematol; 1994 Jun; 7(2):321-37. PubMed ID: 7803904
[TBL] [Abstract][Full Text] [Related]
49. Treatment outcome in children with central nervous system-positive Burkitt lymphoma using only intrathecal and systemic chemotherapy combined with rituximab.
Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Zhang YH
Chin Med J (Engl); 2021 Mar; 134(11):1329-1334. PubMed ID: 33734131
[TBL] [Abstract][Full Text] [Related]
50. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95.
Woessmann W; Seidemann K; Mann G; Zimmermann M; Burkhardt B; Oschlies I; Ludwig WD; Klingebiel T; Graf N; Gruhn B; Juergens H; Niggli F; Parwaresch R; Gadner H; Riehm H; Schrappe M; Reiter A;
Blood; 2005 Feb; 105(3):948-58. PubMed ID: 15486066
[TBL] [Abstract][Full Text] [Related]
51. Effective multi-agent chemotherapy for advanced abdominal lymphoma and FAB L3 leukemia of childhood.
Toogood IR; Tiedemann K; Stevens M; Smith PJ
Med Pediatr Oncol; 1993; 21(2):103-10. PubMed ID: 8433675
[TBL] [Abstract][Full Text] [Related]
52. Modified BFM protocol for childhood acute lymphoblastic leukemia: a retrospective analysis.
Aziz Z; Zahid M; Mahmood R; Maqbool S
Med Pediatr Oncol; 1997 Jan; 28(1):48-53. PubMed ID: 8950336
[TBL] [Abstract][Full Text] [Related]
53. Management of Non-Hodgkin Lymphoma: ICMR Consensus Document.
Thacker N; Bakhshi S; Chinnaswamy G; Vora T; Prasad M; Bansal D; Agarwala S; Kapoor G; Radhakrishnan V; Laskar S; Kaur T; Rath GK; Dhaliwal RS; Arora B
Indian J Pediatr; 2017 May; 84(5):382-392. PubMed ID: 28378140
[TBL] [Abstract][Full Text] [Related]
54. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma.
Patte C; Kalifa C; Flamant F; Hartmann O; Brugières L; Valteau-Couanet D; Bayle C; Caillaud JM; Lemerle J
Med Pediatr Oncol; 1992; 20(2):105-13. PubMed ID: 1734214
[TBL] [Abstract][Full Text] [Related]
55. Improved Outcome of Newly Diagnosed Childhood Mature B-Cell Lymphoma/Leukemia With High Tumor Burden Treated With BFM95-based Protocol Combining Rituximab: A Report From Shanghai, China.
Fu Y; Wang H; Zhai X; Qian X; Meng J; Miao H; Zhu X; Yu Y; Lu F
J Pediatr Hematol Oncol; 2019 Apr; 41(3):170-174. PubMed ID: 30664102
[TBL] [Abstract][Full Text] [Related]
56. [Outcomes of modified NHL-BFM-90 protocol for children and adolescents with lymphoblastic lymphoma].
Sun X; Zhen Z; Zhu J; Wang J; Lu S; Xia Y; Sun F; Chen Y; Zhang F; Cai R; Li P; Guo X
Zhonghua Xue Ye Xue Za Zhi; 2014 Dec; 35(12):1083-9. PubMed ID: 25543702
[TBL] [Abstract][Full Text] [Related]
57. Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group.
Sposto R; Meadows AT; Chilcote RR; Steinherz PG; Kjeldsberg C; Kadin ME; Krailo MD; Termuhlen AM; Morse M; Siegel SE
Med Pediatr Oncol; 2001 Nov; 37(5):432-41. PubMed ID: 11745871
[TBL] [Abstract][Full Text] [Related]
58. Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report.
Stark B; Sharon R; Rechavi G; Attias D; Ballin A; Cividalli G; Burstein Y; Sthoeger D; Abramov A; Zaizov R
Cancer; 2000 Jan; 88(1):205-16. PubMed ID: 10618625
[TBL] [Abstract][Full Text] [Related]
59. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
[TBL] [Abstract][Full Text] [Related]
60. Burkitt lymphoma in children: the Israeli experience.
Eldar AH; Futerman B; Abrahami G; Attias D; Barak AB; Burstein Y; Dvir R; Gabriel H; Horovitz J; Kapelushnik J; Kaplinsky H; Miskin H; Sthoeger D; Toren A; Vilk-Revel S; Weintraub M; Yaniv I; Linn S; Arush MB
J Pediatr Hematol Oncol; 2009 Jun; 31(6):428-36. PubMed ID: 19648792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
